The company Galerías del Tresillo organises every year during the month of October the ‘Pink Days’. During these days, customers are offered products at a special discount and can also decide how many minutes they want to donate to breast cancer research at the VHIO.
A relationship that began three years ago and that, today, continues with an annual collaboration dedicated to the research of this disease.
As a token of support for breast cancer research and awareness, the leading sofa company in Catalonia donated €1,000 to VHIO’s Breast Cancer Group.
Valentina Pizzolón, Director of Marketing and Digital Strategy at Galerías del Tresillo explains: “During the Pink Days we set up a web and in-store gateway so that customers could contribute more minutes to the research and we dyed the shops pink.
And she comments: “It is a pleasure to come and present the donation cheque to Dr. Saura and to continue collaborating with VHIO. With the intention of being able to do more actions in the near future”.
The VHIO Breast Cancer Group will be giving a talk to the company’s employees on the prevention and treatment of breast cancer today in thanks for the donation.
Collaborating with the VHIO Breast Cancer Group
The donation will go to the Breast Cancer Group so that research projects that need more resources to move forward can be initiated.
Dr. Saura, referring to the donations received in recent years, explains: “Thanks to donations, such as the one from Galerías del Tresillo, and other contributions from donors, we were able to start the breast milk liquid biopsy project”.
“We are very grateful for the donations because they help us to initiate projects that, in the future, will help in the treatment of breast cancer patients and the design of new therapies” she explains.
The VHIO Breast Cancer Group’s main area of expertise is clinical research focused on drug development and associated translational research.
The group is currently working on different lines of research such as the optimisation of therapies, with the introduction of new treatments to combat cancer resistance mechanisms.
As well as introducing proteomics and genomics platforms and liquid biopsy techniques in translational research to advance the understanding of tumour biology and the use of preclinical data to design innovative clinical trials for advanced diseases in the future.
